VivoSeq
Infectious Disease

HIV

42

Pipeline Programs↗

62

Active Trials↗

29

Companies Involved↗

HIV is a moderately active landscape with 42 programs across 29 companies. The most active players are Moderna, Boehringer Ingelheim, Viatris Specialty LLC. 3 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

60/100

Mech. Concentration

13/100

Completion Rate

92/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Moderna logo

Moderna

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical3

GVHD Prophylaxis

National Cancer Institute (NCI)

Plerixafor

Genzyme, a Sanofi Company

Maraviroc

GSK

Phase 16

Mrna-1040

Moderna

DV700P-RNA

National Institute of Allergy and Infectious Diseases (NIAID)

DV701B1.1-RNA

National Institute of Allergy and Infectious Diseases (NIAID)

CAB LA

GSK

DV201P-RNA

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 215

Gabapentin

Viatris Specialty LLC

Bariticinib

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Chadox1.thivconsv1

University of Oxford

Chadox1.hivconsv62

National Institute of Allergy and Infectious Diseases (NIAID)

Mva.thivconsv4

University of North Carolina, Chapel Hill

Phase 315

Islatravir

Merck & Co.

Lenacapavir

Gilead

INCMGA00012

Incyte

F/TAF

Gilead

Dolutegravir

GSK

Approved3

Cabotegravir

GSK

Doravirine

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

DTG/ABC/3TC

Harvard School of Public Health (HSPH)

Analysis

Modality Breakdown

97%

Small molecule

36 of 37 classified programs — the dominant modality here.

3%ALL OTHERSRNA therapy13%

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 81% of 58 pipeline programs.

Analysis

Trial Status

264

clinical trials

Completed171 · 65%
Recruiting25 · 9%
Not yet recruiting20 · 8%
Active, not recruiting15 · 6%
Unknown status15 · 6%
Terminated10 · 4%
Other8 · 3%

Clinical Trials

Trial Activity

264 trials

Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
Recruiting·UUniversity Hospital, Montpellier·N/A·NCT06441123·24 enrolled
DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
Recruiting·UUniversity Hospital, Caen·Phase 2·NCT06034938·32 enrolled
CHIPP-PrEP: Cabotegravir-Hormone Interrogation of Pharmacokinetics/Pharmacodynamics (PK/PD) for HIV Prevention
Recruiting·JJohns Hopkins University·Phase 1·NCT07672717·32 enrolled
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
Recruiting·BBeijing 302 Hospital·Phase 2·NCT07637877·21 enrolled
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer
Recruiting·National Cancer Institute (NCI)·N/A·NCT00006518·1,029 enrolled
Implementation of a Triadic Network Case Management Intervention for Individuals Living With or Vulnerable to HIV
Recruiting·UUniversity of Chicago·Preclinical·NCT06162897·180 enrolled
A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05470491·265 enrolled
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001281·2,419 enrolled
An Evaluation of HIV-associated Neurocognitive Disorders (HAND) in Virologically Controlled Patients
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT01875588·1,150 enrolled
Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00029445·400 enrolled
AbVax: Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV to Induce a Protective T-cell 'Vaccinal Effect' - a Randomised Phase II Clinical Trial
Recruiting·UUniversity of Oxford·Phase 2·NCT07054931·48 enrolled
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07390474·40 enrolled
Change My Story: Pilot Randomized Clinical Trial of Change My Story Among Young Persons Living With HIV and Depression
Recruiting·MMassachusetts General Hospital·Preclinical·NCT06389565·80 enrolled
A Community-based Adaptation of a Peer-led Intervention to Address Alcohol Use and HIV Risk in Pregnant Women in South Africa (Mentor Moms+)
Recruiting·UUniversity of California, Los Angeles·Preclinical·NCT06962592·100 enrolled
A Study of Viral Burden in Peripheral Blood Versus Lymphoid and Bone Marrow Tissue in People Living With HIV
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001316·400 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)